Stock (Symbol) |
Johnson & Johnson (JNJ) |
Stock Price |
$104 |
Sector |
| Healthcare |
Data is as of |
| February 24, 2016 |
Expected to Report |
| Apr 12 – Apr 18 |
Company Description |
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices.Source: Thomson Financial |
Sharek’s Take |
One Year Chart |
This stock was has built a long base and just yesterday broke out to a new high of $106. This breakout is significant, as investors are in search of safe growth. But growth isn’t strong. 5% last qtr as sales declined 2%. I think investors are looking forward to estimates 3 and 4 qtrs out, where 8% and 9% profit growth is expected. |
Fair Value |
This stock sells for 16x earnings, which doesn’t make it cheap. As you can see in the table to the right JNJ sold for 12 to 14 times earnings after the 2008 market crash. Still, I think stock has legs and can make a solid move higher right now. My Fair Value is 17x earnings, but the P/E could get to 19 or 20. |
Bottom Line |
Johnson & Johnson a great stock for conservative investors searching for growth in an environment where CDs aren’t paying squat. This stock gets the highest grades for safety and has a 3% dividend that’s increased annually for more than 50 years. The two negatives are JNJ is dealing with a strong dollar and the long-term estimated total annual return is only 8% per year JNJ will rank 23rd of 34 stocks in the Conservative Portfolio Power Rankings. |
Power Rankings |
Growth Stock Portfolio
N/AAggressive Growth Portfolio N/AConservative Stock Portfolio 23 of 34 |

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices.
This stock was has built a long base and just yesterday broke out to a new high of $106. This breakout is significant, as investors are in search of safe growth. But growth isn’t strong. 5% last qtr as sales declined 2%. I think investors are looking forward to estimates 3 and 4 qtrs out, where 8% and 9% profit growth is expected.
This stock sells for 16x earnings, which doesn’t make it cheap. As you can see in the table to the right JNJ sold for 12 to 14 times earnings after the 2008 market crash. Still, I think stock has legs and can make a solid move higher right now. My Fair Value is 17x earnings, but the P/E could get to 19 or 20.
Johnson & Johnson a great stock for conservative investors searching for growth in an environment where CDs aren’t paying squat. This stock gets the highest grades for safety and has a 3% dividend that’s increased annually for more than 50 years. The two negatives are JNJ is dealing with a strong dollar and the long-term estimated total annual return is only 8% per year JNJ will rank 23rd of 34 stocks in the